NeuroMab™ Anti-CD38 BBB Shuttle Antibody(NRZP-1022-ZP3883)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

ADCC; CDC; FC; In Vitro

Relevant Diseases

Parkinson's Disease; Multiple Sclerosis

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CD38

Official Name

CD38

Full Name

CD38 molecule

Alternative Names

Acute lymphoblastic leukemia cells antigen CD38;
ADP ribosyl cyclase 1;
ADP ribosyl cyclase;
ADP ribosyl cyclase/cyclic ADP-ribose hydrolase;
ADP-ribosyl cyclase 1;
ADPRC 1;
ADPRC1;
cADPr hydrolase 1;
CD 38;

Product Pictures

CDC

Figure 1A CDC mediated by CD38 antibody HuMAb 005 mutant on CD38 positive cells.

Figure 1A CDC efficacy of a series of 005 mutants on Daudi cells.

CDC

Figure 1B CDC mediated by the CD38 antibody HuMAb 005 mutant on CD38-positive cells.

1B CDC efficacy of HuMAb 005 mutants at a range of concentrations on Raji cells.

CDC

Figure 2 CDC of wild-type and E345R mutants of the CD38 antibody HuMAb 005 in competition experiments with Fc-binding peptides.

ADCC

Figure 3 ADCC of wild-type CD38 antibody HuMAb 005 and mutant IgG1-005-E345R on CD38-expressing Daudi cells. ADCC of PBMC from one donor is shown, depicted as percent lysis.

CDC

Figure 4 CDC on CD20 and CD38 positive Wien133 cells.

CDC

Figure 5 CDC on CD20 and CD38 positive Wien133 cells.

FuncS

Figure 6 In vivo efficacy assessment of IgG1-005-E345R in a subcutaneous xenograft model with Raji-luc #2D1 cells.

FuncS

Figure 7 In vivo efficacy assessment of IgG1-005-E345R in a subcutaneous xenograft model with Raji-luc #2D1 cells.

FuncS

Figure 8A Introduction of the Fc-Fc stabilizing E345R mutation in wild-type CD38 antibody 005 resulted in enhanced killing of primary CLL cells in an ex vivo CDC assay (mean ± standard error of the mean).

FuncS

Figure 8B Introduction of the Fc-Fc stabilizing E345R mutation in wild-type CD38 antibody 005 resulted in enhanced killing of primary CLL cells in an ex vivo CDC assay (mean ± standard error of the mean).

Publications